Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTwP-HepB-Hib-IPV(Sabin)
- Development stage
- Preclinical
- Lead developer
- Techinvention Lifecare
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTwP-HepB-Hib-IPV(Sabin) is a hexavalent combination vaccine being developed by Techinvention Lifecare. It is designed to provide protection against six major childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, Haemophilus influenzae type b (Hib) disease, and poliomyelitis. The vaccine formulation includes diphtheria toxoid, tetanus toxoid, whole-cell Bordetella pertussis (wP) antigens, hepatitis B surface antigen, Haemophilus influenzae type b conjugate, and inactivated poliovirus based on Sabin strains (sIPV). By combining these six antigens into a single injection, the vaccine aims to simplify immunization schedules, improve compliance, and reduce the logistical burden on healthcare systems in developing regions. It is currently in the preclinical development stage.
- Other names
- Hexavalent combination vaccine (Techinvention Lifecare)diphtheria + tetanus + whole-cell pertussis + hepatitis b + haemophilus influenzae type b + inactivated poliovirus (Sabin)
02
Targets
HBsAg (Hepatitis B surface antigen)PRR (Pattern recognition receptors)Diphtheria toxinpMHC–TCR (Peptide–MHC–T-cell receptor complex)
Beyond the preview
Go deeper on DTwP-HepB-Hib-IPV(Sabin).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTwP-HepB-Hib-IPV(Sabin).